Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Biofrontera Inc. (BFRI)

1.05   0 (0%) 12-02 15:55
Open: 1.07 Pre. Close: 1.05
High: 1.07 Low: 1
Volume: 63,676 Market Cap: 28(M)

Technical analysis

as of: 2022-12-02 4:21:14 PM
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 1.3     One year: 1.52
Support: Support1: 0.93    Support2: 0.81
Resistance: Resistance1: 1.11    Resistance2: 1.3
Pivot: 1.01
Moving Average: MA(5): 1.04     MA(20): 0.99
MA(100): 1.19     MA(250): 2.71
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 88.8     %D(3): 90.4
RSI: RSI(14): 52.9
52-week: High: 14.63  Low: 0.81
Average Vol(K): 3-Month: 148 (K)  10-Days: 38 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ BFRI ] has closed below upper band by 19.7%. Bollinger Bands are 65% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.07 - 1.08 1.08 - 1.08
Low: 0.99 - 0.99 0.99 - 1
Close: 1.04 - 1.05 1.05 - 1.06

Company Description

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was founded in 1997 and is headquartered in Woburn, Massachusetts.

Headline News

Wed, 30 Nov 2022
Biofrontera Inc. to Participat -

Thu, 24 Nov 2022
Pearl farming: Opening new horizons for farmers - The Business Standard

Mon, 14 Nov 2022
Biofrontera, Inc. (BFRI) Q3 2022 Earnings Call Transcript - Seeking Alpha

Mon, 14 Nov 2022
Biofrontera Inc. (BFRI) Reports Q3 Loss, Tops Revenue Estimates - Nasdaq

Tue, 08 Nov 2022
Biofrontera Inc. Fully Exercises Recently Acquired Options to Purchase Shares of Biofrontera AG - Yahoo Finance

Fri, 04 Nov 2022
German Management Consulting Firm Abshagen Consulting Takes Significant Position in BFRI / Biofrontera - Nasdaq

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers—Specialty & Generic
Shares Out. 27 (M)
Shares Float 15 (M)
% Held by Insiders 42.3 (%)
% Held by Institutions 7.6 (%)
Shares Short 540 (K)
Shares Short P.Month 268 (K)

Stock Financials

EPS -2.59
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.95
Profit Margin (%) -44.7
Operating Margin (%) -38.7
Return on Assets (ttm) -19
Return on Equity (ttm) -474.1
Qtrly Rev. Growth -0.4
Gross Profit (p.s.) 0.42
Sales Per Share 1.03
EBITDA (p.s.) -0.39
Qtrly Earnings Growth 0
Operating Cash Flow -29 (M)
Levered Free Cash Flow -12 (M)

Stock Valuations

PE Ratio -0.41
PEG Ratio 0
Price to Book value 1.09
Price to Sales 1.01
Price to Cash Flow -0.97

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.